September 2022 "G-protein-coupled receptors (GPCRs) are involved in a wide array of physiological and disease

September 2022 "G protein‐coupled receptors (GPCRs) are valuable therapeutic targets for many diseases

including expensive cost of reagents, optimizing sensor expression levels and adapting these systems to disease-relevant the development of the BERKY and the ONE-GO biosensors, designed to facilitate their application in disease

The mGlu5 receptor is a promising target for the treatment of psychiatric and neurodegenerative diseases

receptor type 9 (CCR9) antagonist and previous phase III clinical candidate for the treatment of Crohn's disease

free fatty acid receptors (FFARs), now regarded as targets for therapeutic intervention for metabolic diseases such as liver disease, obesity and diabetes (Secor et al. 2021; Wold and Zhou 2018).

Receptors: Insights into Potential Therapeutic Opportunities for COVID-19, Heart Failure, and Alzheimer's Disease Reviews, GPCRs, and more Cell-trafficking impairment in disease-associated LPA6 missense mutants and

to Develop and Commercialize Novel COVID-19 and Other Antibody Therapeutics for Difficult to Treat Diseases

Potential Implications for Idiopathic Pulmonary Fibrosis "Idiopathic pulmonary fibrosis (IPF) is a disease

focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases

Moreover, the dysregulation of TLR4 contributes to numerous diseases, which highlights the importance

optic nerve crush in mice "Glaucoma is an optic neuropathy and is currently one of the most common diseases

using next-generation GRABNE sensors Reviews, GPCRs, and more Advances in GPCRs: Structure, Mechanisms, Disease Therapeutics Secures VLAIO Grant Supporting Drug Discovery & Development In Endocrine And Metabolic Diseases

patient outcomes "Triple-negative breast cancer (TNBC) is a particularly aggressive and heterogeneous disease

Cells: Implications for Targeted Therapy "Pancreatic ductal adenocarcinoma (PDAC) remains an aggressive disease

suggests that Fgr interacts with arrestin-3 at multiple sites and is consistent with the locations of disease-associated

However, an imbalance in the chemokine system can also contribute to various diseases, such as inflammatory

free fatty acid receptors (FFARs), now regarded as targets for therapeutic intervention for metabolic diseases such as liver disease, obesity and diabetes (Wold and Zhou 2018).

While these small protein GPCRs are valuable drug targets linked to serious diseases, many remain undrugged antagonist analogs have demonstrated powerful efficacies across a range of animal models spanning different disease Since many inflammatory diseases are driven by inappropriate recruitment of monocytes into tissues, CCR2 diversified portfolio of GPCR-targeted drug candidates for the treatment of cancer and other serious diseases Journal of Infectious Diseases, 199, 1525-1527. https://doi.org/10.1086/598685 · Demonstration

G protein-coupled receptors (GPCRs) have been shown to play integral roles in Alzheimer's disease pathogenesis

Mutations in G protein-coupled receptors (GPCRs) underlie numerous diseases.

distinct from odor perception, and may contribute to the pathogenesis of disorders including brain diseases

With this high-resolution, dynamic view of GPCR activation, scientists can better tackle diseases by

Schizophrenia Sphingosine 1-phosphate receptor subtype 1 (S1P1) activity in the course of Alzheimer's disease

whether these CB1 receptors contribute to pathways underlying skeletal muscle biological function and disease

Immunology CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment of Inflammatory Diseases

participates in inflammatory and immune responses that have been found to mediate apoptosis in autoimmune disease

unveil new dimensions of GPCR functionality and offer innovative approaches to treating a wide range of diseases